Depression and cancer: How psilocybin from mushrooms can help
Psilocybin, a hallucinogenic substance from certain mushrooms, showed promise in reducing depression symptoms in a phase two trial, with 80% of participants showing sustained response and 50% achieving full remission. Despite being classified as a Schedule I drug with no accepted medical use, the study highlights its potential for psychological treatment, especially in cancer patients. The trial emphasized a group therapy approach, with participants reporting significant improvements and positive experiences. However, further research with larger groups and control arms is needed to fully understand its efficacy and implications.
Reference News
Psilocybin, a hallucinogenic substance from certain mushrooms, showed promise in reducing depression symptoms in a phase two trial, with 80% of participants showing sustained response and 50% achieving full remission. Despite being classified as a Schedule I drug with no accepted medical use, the study highlights its potential for psychological treatment, especially in cancer patients. The trial emphasized a group therapy approach, with participants reporting significant improvements and positive experiences. However, further research with larger groups and control arms is needed to fully understand its efficacy and implications.